Non-injection weight loss drugs: what's licensed in the UK right now

You'd rather swallow a tablet — and now there's a licensed one for weight loss

Picture this: you've done your research, you meet the BMI criteria, and you're genuinely ready to try a GLP-1 medicine. But every time you get close to booking a consultation, the thought of self-injecting once a week puts you off. That's a common reaction, and for most of 2024 and 2025 there was no neat answer: the licensed injectable options were well-evidenced and effective, but tablets simply weren't available for weight management in the UK.

That changed on 11 June 2026, when the MHRA approved Wegovy tablets as the first oral GLP-1 medicine licensed in the UK for weight loss. The active ingredient is semaglutide, the same molecule in the Wegovy injection, but reformulated with an absorption enhancer called SNAC so that it can survive the stomach environment and enter the bloodstream via the gut wall. You take it once daily, first thing in the morning on an empty stomach with a small sip of plain water, then wait at least 30 minutes before breakfast, coffee, or other medicines.

The dosing works as a gradual escalation: starting at 1.5 mg, then 4 mg, then 9 mg, and finally the 25 mg maintenance dose, spending at least a month at each level. A prescriber manages that titration, not the patient independently. Because the tablets are stored at room temperature with no refrigeration, they're also more straightforward to travel with than a pen that needs to stay chilled.

The MHRA licensed it for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure or high cholesterol, used alongside a reduced-calorie diet and increased physical activity. See how the injections compare if you'd like to understand the alternative before deciding.

What the trial evidence actually showed — and what it didn't

The approval rested primarily on a phase-3 trial called OASIS 4, which followed 307 adults with obesity or overweight plus at least one weight-related condition over 64 weeks. Participants weren't living in a clinical bubble: they had lifestyle support alongside the medicine, which reflects real-world use better than a pure pharmacology study.

The headline result was around 13.6% average body-weight reduction in the semaglutide group versus roughly 2.4% in the placebo group. Among people who adhered fully throughout the trial, the average reached about 17%. The distinction matters: if you quote the 17% figure, it belongs specifically to the fully-adherent group, not as a general average anyone should plan around.

The most common side effects in the trial were gastrointestinal: nausea, diarrhoea, vomiting and constipation were reported in around 74% of those taking the oral semaglutide, compared with roughly 42% on placebo. That's a higher rate than you'd hear with the injection formulation, partly because oral bioavailability of semaglutide is lower, so the dose needed to achieve therapeutic effect is higher in relative terms. GI effects were generally mild to moderate and most settled over the first few weeks of a dose level. The NHS semaglutide medicines page has a full rundown of side effects, including the ones that warrant prompt medical attention.

Wegovy tablets are not available on the NHS at launch: a NICE appraisal would be required first, and none has been published as of summer 2026. A private prescription is the only current route.

Orlistat: the longer-standing non-injection option

Before oral GLP-1s arrived, orlistat was the only widely available non-injection prescription option for weight loss in the UK, and it's worth understanding how different it is. Orlistat doesn't act on appetite hormones at all. It inhibits the enzyme lipase in the gut, blocking absorption of around a third of the fat you eat, so that fat passes through and is excreted. You take it with each main meal, or within an hour of eating.

The practical implication is that orlistat works alongside what you eat, not in spite of it. A high-fat meal leads to oily, urgent stools, an effect that many people find motivating in a back-to-front way, and that others find difficult to manage socially. It comes in both prescription-strength (120 mg) and lower-strength (60 mg) over-the-counter versions, though the OTC version is sold under different brand names and isn't quite the same conversation as a GLP-1 prescription. The NHS orlistat page covers dosing, who it suits, and the side-effect profile in plain language.

Orlistat tends to produce more modest weight loss than the GLP-1 class overall, though for some people it's a better fit given their health history, other medicines they're taking, or personal preference. It's a genuine clinical option, not a consolation prize. A prescriber is the right person to weigh that up with you. Not all weight-loss drugs are injections, that page goes deeper on the full landscape if you want to read further.

How a prescriber decides which option fits

The choice between an oral medicine and an injection isn't yours to make in isolation, and that's not bureaucratic gatekeeping: it genuinely matters. Both GLP-1 medicines and orlistat interact with other drugs, carry contraindications, and aren't appropriate in pregnancy, breastfeeding or for under-18s. Oral semaglutide has specific absorption requirements that mean the 30-minute morning window isn't optional, if your mornings are the kind where you're out the door before the kettle boils, that's worth discussing with a prescriber before committing. Tirzepatide (Mounjaro), the injectable GLP-1/GIP dual agonist, may be a better evidential fit for some people; weight-loss drugs that use injections covers the injectable options if you want a comparison.

A prescriber also looks at your full picture: existing conditions, current medicines, weight history, and what you've tried before. For oral semaglutide, your BMI, any weight-related comorbidities, and readiness to follow the strict morning-dosing routine all feed into the clinical assessment. If you're based on the south coast, our guide to weight loss injections in Bournemouth explains local access and what to expect from a consultation in that area. Cost context for injectable options is worth reading too, since price is a practical factor for many people choosing between formats. To find out which prescription option a nume prescriber would consider appropriate for you, check your eligibility with a free consultation, reviewed the same day by a real clinician, not a scoring algorithm.